Dyslipidemia and Rate of Under-Target Low-Density Lipoprotein-Cholesterol in Patients with Coronary Artery Disease in KoreaDyslipidemia and Rate of Under-Target Low-Density Lipoprotein-Cholesterol in Patients with Coronary Artery Disease in Korea
- Other Titles
- Dyslipidemia and Rate of Under-Target Low-Density Lipoprotein-Cholesterol in Patients with Coronary Artery Disease in Korea
- Authors
- 이상학; 송우혁; 정명호; 허승호; 전동운; 정원주; Anselm K Gitt; Martin Horack; Ami Vyas; Dominik Lautsch; Baishali Ambegaonkar; Philippe Brudi; 장양수
- Issue Date
- 2019
- Publisher
- 한국지질동맥경화학회
- Keywords
- Cholesterol; Hydroxymethylglutaryl-CoA reductase inhibitors; Acute coronary syndrome; Coronary artery disease; Dyslipidemias
- Citation
- 지질·동맥경화학회지, v.8, no.2, pp.242 - 251
- Indexed
- KCI
OTHER
- Journal Title
- 지질·동맥경화학회지
- Volume
- 8
- Number
- 2
- Start Page
- 242
- End Page
- 251
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/131561
- DOI
- 10.12997/jla.2019.8.2.242
- ISSN
- 2287-2892
- Abstract
- Objective: The aim of this study was to evaluate under target rates of low-density lipoproteincholesterol (LDL-C) in Korean patients with stable coronary artery disease (CAD) or an acute coronary syndrome (ACS) in real world practice.
Methods: Dyslipidemia International Study II was an international observational study of patients with stable CAD or an ACS. Lipid profiles and use of lipid-lowering therapy (LLT) were documented at enrollment, and for the ACS cohort, 4 months follow-up was recommended.
Rates of under target LDL-C as per European guidelines, were evaluated, and multivariate regression was performed to identify predictive factors of patients presenting under the target.
Results: A total of 808 patients were enrolled in Korea, 500 with stable CAD and 308 with ACS. Of these, 90.6% and 52.6% were being treated with LLT, respectively. In the stable CAD group, 40.0% were under target LDL-C, while in ACS group, the rate was 23.7%. A higher statin dose was independently associated with under target LDL-C in both groups (OR, 1.03; p=0.046 [stable CAD] and OR, 1.05; p=0.01 [ACS]). The mean statin dosage (atorvastatin equivalent) was 17 mg/day. In the 79 ACS patients who underwent the follow-up examination, the LDL-C under target rate rose to 59.5%.
Conclusion: Only a minority of patients with stable CAD or ACS were under their target LDL-C level at enrollment. The statin dose was not sufficient in the majority of patients.
These results indicate a considerable LLT gap in Korean patients with established CAD.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.